AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24156737 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor-effort (treatment) condition
Number of subjects: 0
Study 24156737 — intervention group
Group type: COMPARATOR
Intervention: Full-effort (control) condition
Number of subjects: 0
Study 23194432 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 321
Study 23194432 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 321
Study 21823421 — intervention group
Group type: EXPERIMENTAL
Intervention: KXC + MTX
Number of subjects: 240
Study 21823421 — intervention group
Group type: EXPERIMENTAL
Intervention: KXC
Number of subjects: 240
Study 21823421 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 240
Study 18281410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 102
Study 18281410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18281410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (stricter definition)
Number of subjects: 102
Study 18281410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (stricter definition)
Number of subjects: 102
Study 16688999 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for Yiqi Yangyin Quyu (YYQ) and prednisone
Number of subjects: 62
Study 16688999 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (control group)
Number of subjects: 62
Study 12926117 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant therapy
Number of subjects: 0
Study 12926117 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative approach
Number of subjects: 0
Study 10615946 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride infusion
Number of subjects: 14
Study 10615946 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride infusion with hyperinsulinemic clamp
Number of subjects: 14
Study 9187983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported arm training (ARMT)
Number of subjects: 26
Study 9187983 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistive breathing training (RBT)
Number of subjects: 26
Study 1553611 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal interposition hepaticoduodenostomy
Number of subjects: 0
Study 1553611 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y hepaticojejunostomy
Number of subjects: 0
Study 3884880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 11
Study 3884880 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 11
Study 3884880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 11
Study 3884880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29182037 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg/day
Number of subjects: 374
Study 29182037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 29182037 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 374
Study 30177485 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 443
Study 30177485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 27043417 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+CR (Resistance Training plus Caloric Restriction)
Number of subjects: 24
Study 27043417 — intervention group
Group type: COMPARATOR
Intervention: RT (Resistance Training)
Number of subjects: 24
Study 24762560 — intervention group
Group type: EXPERIMENTAL
Intervention: BreastCARE intervention
Number of subjects: 1235
Study 22869571 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-1792 (2 mg/kg i.v. q24h)
Number of subjects: 197
Study 22869571 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g i.v. q12h)
Number of subjects: 197
Study 22869571 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-1792
Number of subjects: 197
Study 22869571 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 197
Study 19927154 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg once daily, increased to 150 mg and then to 300 mg if needed
Number of subjects: 40
Study 17621602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4 mg kg(‐1) h(‐1)
Number of subjects: 30
Study 17621602 — intervention group
Group type: COMPARATOR
Intervention: Desflurane 1 MAC in air
Number of subjects: 30
Study 15809571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task methodology combining cognitive and balance assessments
Number of subjects: 0
Study 15809571 — intervention group
Group type: COMPARATOR
Intervention: Single task performance (cognitive and balance tests independently)
Number of subjects: 0
Study 12441726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon anesthesia as preemptive analgesia
Number of subjects: 30
Study 12441726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preemptive analgesia)
Number of subjects: 30
Study 10850585 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy with intravenous ganciclovir and CMV‐hyperimmunoglobulin
Number of subjects: 31
Study 10850585 — intervention group
Group type: COMPARATOR
Intervention: Therapy only at onset of clinical symptoms (Control)
Number of subjects: 31
Study 8712444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine 12.5 mg
Number of subjects: 0
Study 8712444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine 25 mg
Number of subjects: 0
Study 8712444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine 50 mg
Number of subjects: 0
Study 8712444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine 75 mg
Number of subjects: 0
Study 8712444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine 100 mg
Number of subjects: 0
Study 1922609 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 8
Study 1922609 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 8
Study 1922609 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 8
Study 1922609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 8
Study 1922609 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 8
Study 6178096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CRL) at a dose of 2 ng/kg/min
Number of subjects: 25
Study 6178096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled SBP (≥140 mm Hg)
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled DBP (≥90 mm Hg)
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SBP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous DBP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous PP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous MAP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: PP
Number of subjects: 14598
Study 31160658 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP
Number of subjects: 14598
Study 30477855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard (MU)
Number of subjects: 17
Study 30477855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (GI)
Number of subjects: 17
Study 30477855 — intervention group
Group type: COMPARATOR
Intervention: Warm Water Alone (WA)
Number of subjects: 17
Study 30477855 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall warmth
Number of subjects: 17
Study 30477855 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature at the feet
Number of subjects: 17
Study 30477855 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature at the hands
Number of subjects: 17
Study 26777137 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD plus PR
Number of subjects: 457
Study 26777137 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg QD plus PR
Number of subjects: 457
Study 26777137 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus PR
Number of subjects: 457
Study 25103362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination on present emotions and thoughts
Number of subjects: 30
Study 25103362 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of whatever thoughts and feelings come up
Number of subjects: 30
Study 25103362 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23983966 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day quercetin
Number of subjects: 941
Study 23983966 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day quercetin
Number of subjects: 941
Study 23983966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 19497244 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10, 20, and 40 mg/day (combined)
Number of subjects: 599
Study 19497244 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (combined)
Number of subjects: 599
Study 17256809 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (30 units Botox or 90 units Dysport)
Number of subjects: 100
Study 17256809 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Nitroglycerin ointment applied three times daily for 8 weeks
Number of subjects: 100
Study 17256809 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 100
Study 17256809 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Nitroglycerin ointment
Number of subjects: 100
Study 16118578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild, continuous exercise during decompression (fin underwater swimming at about 30% of maximal oxygen uptake)
Number of subjects: 10
Study 16118578 — intervention group
Group type: COMPARATOR
Intervention: No exercise during decompression (control)
Number of subjects: 10
Study 12473548 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (type 2D) patients
Number of subjects: 3
Study 12473548 — intervention group
Group type: COMPARATOR
Intervention: Essential hypertension (EH) patients
Number of subjects: 3
Study 12473548 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 9795972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lycopene from tomato juice, spaghetti sauce, and tomato oleoresin for a period of one week each
Number of subjects: 19
Study 9795972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lycopene from spaghetti sauce and tomato oleoresin
Number of subjects: 19
Study 9795972 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study 8681500 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-8 mg daily)
Number of subjects: 70
Study 8681500 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5-20 mg daily)
Number of subjects: 70
Study 1977577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral interferon alpha
Number of subjects: 32
Study 1977577 — intervention group
Group type: COMPARATOR
Intervention: Intensive supportive management alone
Number of subjects: 32
Study 341964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological doses of oxytocin (2.6 mU/minute increasing to 422.4 mU/minute)
Number of subjects: 278
Study 341964 — intervention group
Group type: COMPARATOR
Intervention: Physiological doses of oxytocin (2.6 to 13.2 mU/minute)
Number of subjects: 278
Study 31808662 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative airtest (SpO2 assessment on room air)
Number of subjects: 902
Study 31808662 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtest score (based on pre and postoperative SpO2)
Number of subjects: 902
Study 27584139 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Telemedicine (HBT) program for 6 months
Number of subjects: 100
Study 27584139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBT, only recommendation to continue exercising at home)
Number of subjects: 100
Study 26019465 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-FIX
Number of subjects: 105
Study 23849279 — intervention group
Group type: EXPERIMENTAL
Intervention: Households in the top third of monetary expenditures on market foods
Number of subjects: 1199
Study 23849279 — intervention group
Group type: COMPARATOR
Intervention: Households that reported not spending money on market foods
Number of subjects: 1199
Study 22191292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and IV contrast-enhanced MDCT (Gp1)
Number of subjects: 200
Study 22191292 — intervention group
Group type: COMPARATOR
Intervention: Only IV contrast-enhanced MDCT (Gp2)
Number of subjects: 200
Study 19436042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20-min consultation from HSCS and leaflets
Number of subjects: 450
Study 19436042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 60-min consultation, four weekly appointments with HSCS, and leaflets
Number of subjects: 450
Study 19436042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 60-min consultation, four weekly appointments with HSCS, and scheduled appointment at community-based service
Number of subjects: 450
Study 19436042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: HSCS attendance at 55 weeks
Number of subjects: 450
Study 19436042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: HSCS attendance at 55 weeks
Number of subjects: 450
Study 19436042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: HSCS attendance at 55 weeks
Number of subjects: 450
Study 17352353 — intervention group
Group type: EXPERIMENTAL
Intervention: Burr‐hole irrigation
Number of subjects: 80
Study 17352353 — intervention group
Group type: COMPARATOR
Intervention: Burr‐hole drainage
Number of subjects: 80
Study 15313991 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution (1.5% wt/wt diclofenac sodium in a carrier containing dimethyl sulfoxide [DMSO])
Number of subjects: 248
Study 11265924 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses worn for up to 13 nights
Number of subjects: 20
Study 11265924 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenses from Gram-negative bacterial carriers
Number of subjects: 20
Study 9002531 — intervention group
Group type: EXPERIMENTAL
Intervention: RenaGel
Number of subjects: 36
Study 9002531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8288743 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral melatonin
Number of subjects: 12
Study 8288743 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg testosterone propionate i.m. (TP)
Number of subjects: 12
Study 8288743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3086959 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 5 mg a day for patients over 10 kg, 5 mg every two days for patients under 10 kg (3 months)
Number of subjects: 26
Study 3086959 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (3 months)
Number of subjects: 26
Study 3086959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 months)
Number of subjects: 26
Study 29091464 — intervention group
Group type: EXPERIMENTAL
Intervention: T-LPP supplement
Number of subjects: 0
Study 29091464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26750458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigaptide
Number of subjects: 19
Study 26750458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 26750458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 19
Study 24269926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (initial weekly dose of 10 mg, escalating to 25 mg/week) + infliximab (5 mg/kg body weight at weeks 1, 3, 7, and 14, and every 8 weeks thereafter)
Number of subjects: 126
Study 24269926 — intervention group
Group type: COMPARATOR
Intervention: Infliximab alone (5 mg/kg body weight at weeks 1, 3, 7, and 14, and every 8 weeks thereafter)
Number of subjects: 126
Study 23528365 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel with 1% standardized extract of Sphaeralcea angustifolia
Number of subjects: 130
Study 23528365 — intervention group
Group type: COMPARATOR
Intervention: Topical gel with 2% diclofenac
Number of subjects: 130
Study 19393996 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy for endometrioma (group 1)
Number of subjects: 20
Study 19393996 — intervention group
Group type: COMPARATOR
Intervention: Three‐step procedure (group 2)
Number of subjects: 20
Study 18208957 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare units with peripheral devices (blood-pressure monitor, weight scale, glucometer, pulse oximeter) installed in patients' homes, used daily for data collection.
Number of subjects: 22
Study 18208957 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare units
Number of subjects: 22
Study 18208957 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare monitoring
Number of subjects: 22
Study 12110071 — intervention group
Group type: EXPERIMENTAL
Intervention: Early notification (experimental) group
Number of subjects: 103
Study 12110071 — intervention group
Group type: COMPARATOR
Intervention: Delayed notification (control) group
Number of subjects: 103
Study 12110071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 103
Study 12110071 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response after letters of notification
Number of subjects: 103
Study 9725415 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartmate left ventricular assist device implantation combined with isolated right coronary artery bypass grafting
Number of subjects: 1
Study 9725415 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartmate left ventricular assist device implantation
Number of subjects: 1
Study 7648106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3 micrograms per kg per min for 24 hours)
Number of subjects: 19
Study 7648106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 19
Study 7648106 — intervention group
Group type: COMPARATOR
Intervention: Control (fluids without dopamine)
Number of subjects: 19
Study 7648106 — intervention group
Group type: COMPARATOR
Intervention: Dopamine and Control
Number of subjects: 19
Study 2670175 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 39
Study 2670175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 768471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dramamine
Number of subjects: 32
Study 768471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30676465 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal skin-to-skin contact (SSC) shortly after cesarean delivery
Number of subjects: 108
Study 30676465 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 108
Study 30676465 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal skin-to-skin contact (SSC)
Number of subjects: 108
Study 28079773 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent pregnancies (group B, one; group C, two or greater)
Number of subjects: 426
Study 28079773 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent pregnancies complicated with GDM
Number of subjects: 426
Study 28079773 — intervention group
Group type: COMPARATOR
Intervention: No subsequent pregnancies (group A)
Number of subjects: 426
Study 28079773 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 426
Study 25484177 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (30mg/day; 15mg BID) plus SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day)
Number of subjects: 40
Study 25484177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two placebo tablets per day) plus SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day)
Number of subjects: 40
Study 23532801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-grass pollen tablets
Number of subjects: 0
Study 21252745 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 10 mg daily for 3 days followed by 800 micrograms of vaginal misoprostol
Number of subjects: 168
Study 21252745 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days followed by 800 micrograms of vaginal misoprostol
Number of subjects: 168
Study 21252745 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole group
Number of subjects: 168
Study 21252745 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 168
Study 19276230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion to obtain appropriate FFA concentrations
Number of subjects: 8
Study 19276230 — intervention group
Group type: COMPARATOR
Intervention: Acipimox to suppress FFA levels
Number of subjects: 8
Study 17984152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural care model
Number of subjects: 62
Study 17984152 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up care
Number of subjects: 62
Study 15709358 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose larval therapy
Number of subjects: 0
Study 15709358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bagged larval therapy
Number of subjects: 0
Study 15709358 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel (standard debridement intervention)
Number of subjects: 0
Study 11149997 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 1034
Study 11149997 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast (ZA)
Number of subjects: 1034
Study 9389277 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1 i.v. before induction of anaesthesia
Number of subjects: 60